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Objectives: To determine the point prevalence of carbapenem-non-susceptible Enterobacteriaceae (CNSE) and
carbapenemase-producing Enterobacteriaceae (CPE) isolates among hospitalized patients in Belgium.
Methods: Twenty-four hospital-based laboratories prospectively collected 200 non-duplicated Enterobacteria-
ceae isolates from clinical specimens of hospitalized patients over a 2 month period. All isolates were screened
locally for decreased susceptibility to carbapenem drugs using a disc diffusion method according to CLSI inter-
pretative criteria. CNSE strains were referred centrally for confirmation of carbapenemase by phenotypic and
molecular testing.
Results: From February to April 2012, 158 of the 4564 screened Enterobacteriaceae isolates were categorized
as non-susceptible to carbapenems, resulting in a point prevalence of CNSE of 3.5% (95% CI: 2.9%–4.2%;
range per centre: 0.5%–8.5%). Of the 125 referred CNSE isolates, 11 Klebsiella pneumoniae isolates [OXA-48
(n¼7), KPC type (n¼3) and NDM type (n¼1)], 1 OXA-48-positive Escherichia coli isolate and 1 KPC-positive Kleb-
siella oxytoca isolate were detected in eight hospitals. None of the 72 carbapenem-non-susceptible Enterobac-
ter spp. isolates were confirmed as CPE. The minimal estimated point prevalence of CPE isolates was 0.28% (13/
4564; 95% CI: 0.13%–0.44%) overall (range per centre: 0%–1.5%).
Conclusions: Despite the overall low prevalence of CNSE found in this study, the detection of CPE isolates in
one-third of the participating centres raises concerns and highly suggests the spread and establishment of
CPE in Belgian hospitals.
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Introduction
Acquired carbapenemases in Enterobacteriaceae have been
reported extensively worldwide.1 Asymptomatic carriage and in-
fection caused by carbapenemase-producing Enterobacteria-
ceae (CPE) isolates currently raise major public health concerns
for individual therapeutic management and collective infection-
control issues.2 The prevalence of carbapenem resistance and
the types of carbapenemases found in Europe vary between
countries.3,4 In Belgium, a rapid increase in the number of CPE
has been observed since 2010.5
The present cross-sectional survey aimed to estimate
the prevalence of carbapenem-non-susceptible Enterobacteria-
ceae (CNSE) isolates and CPE isolates collected in Belgian
hospitals.
Methods
Study design, inclusion criteria and testing at
participating centres
Twenty-four hospital-based laboratories (Table S1, available as Supple-
mentary data at JAC Online), representing 25% of all acute hospitals
and equally distributed in the different geographical regions of Belgium,
were requested to collect consecutively 200 Enterobacteriaceae isolates
over a period of 2 months from hospitalized patients. Only the first isolate
of the same species per patient was included. Sample collection, culture
and bacterial identification were performed according to local guidelines.
None of the participating hospitals had been confronted with a CPE out-
break at the time of the study.
All isolates were tested locally for susceptibility to meropenem
(10 mg), imipenem (10 mg) and ertapenem (10 mg) by a disc diffusion
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method according to CLSI guidelines.6 All testing materials purchased
from the same manufacturer (Oxoid, Basingstoke, UK) had the same
manufacture batch number, in order to avoid interlot variation. Escheri-
chia coli ATCC 25922 was tested as a quality-control strain in each
centre during the survey.
Enterobacteriaceae isolates showing a decreased susceptibility to any
of the three carbapenems were defined as CNSE and had to be referred to
the reference laboratory. For Proteus, Morganella and Providencia spp. in-
trinsically less susceptible to imipenem, only meropenem and/or ertape-
nem zone sizes were considered.
Characterization of resistance mechanisms and data
analysis
All putative CNSE isolates sent to the reference laboratory were tested for
carbapenemase production by the imipenem hydrolysis-based Carba NP
test7 and underwent multiplex PCR targeting blaVIM, blaIMP, blaNDM, blaKPC
and blaOXA-48 for the detection of carbapenemase-encoding genes.
8 For
confirmed CPE isolates, the MIC values of 14 antimicrobial agents, includ-
ing carbapenems, were determined by a broth microdilution method
(Sensititrew, Trek Diagnostic Systems, Cleveland, OH, USA). The MIC
value of temocillin was determined by an Etest method (bioMe´rieux,
Marcy l’E´toile, France). Susceptibility categorization was interpreted
according to CLSI interpretative criteria6 for all antimicrobial agents
except tigecycline (2012 EUCAST clinical breakpoints v2.0)9 and temocillin
(breakpoints according to Fuchs et al.10). In carbapenemase-negative
CNSE isolates, extended-spectrum b-lactamase (ESBL) production was
sought by a combined double-disc test with cephalosporin indicators
according to CLSI guidelines6 and AmpC cephalosporinase by a boronic
acid-based disc potentiation test.11
Susceptibility rates for the three carbapenems tested and the preva-
lence of CNSE isolates and CPE isolates were calculated globally, for each
centre and also by species or genus.
Results and discussion
In total, 4564 isolates were screened by the 24 participating la-
boratories from February to April 2012. A mean number of 190
isolates per laboratory were tested and only one centre screened
,150 isolates. Roughly one-third each of the 158 CNSE isolates
were isolated from urine (n¼53) and from lower respiratory
tract samples (n¼49). Medical care and intensive care units
(ICUs) were the two wards with the highest number of CNSE iso-
lates (59 and 51, respectively). The highest proportion of CNSE
isolates was found in ICUs (6.9%).
The number of tested and referred isolates per species and
the proportion of carbapenem non-susceptibility are reported in
Table 1. The global point prevalence of CNSE isolates was 3.5%
(158/4564; 95% CI: 2.9%–4.2%) and it ranged per centre from
0.5% to 8.5%. The rate of imipenem non-susceptibility found in
Klebsiella pneumoniae (3.5%; 16/451) is much higher than the
rates reported by European Antimicrobial Resistance Surveillance
Network (EARS-Net) data in 2011 for Belgium (0.4%) and its
neighbouring countries (0.1% in France, 0.2% in Germany and
0.3% in the Netherlands).12 However, EARS-Net is a passive sur-
veillance programme for which there is great variability between
countries regarding data contribution and methodology used.
Therefore, we believe that active national or regional epidemio-
logical studies using standardized protocols are warranted to
measure more accurately the burden of carbapenem resistance.
The strength of our study was the particular attention to the use
of identical materials and testing methods, to minimize variation
in the results due to technical interlaboratory variability.
Overall, Enterobacter spp. together accounted for more than
half of the referred CNSE isolates (72/125), but none of these iso-
lates could be confirmed as CPE. These results confirm the poor
positive predictive value of ertapenem (15% in our study) in a
low-prevalence setting for the detection of CPE isolates mostly
in Enterobacter spp. in which carbapenem resistance usually
reflects the combination of hyperproduced AmpC with imperme-
ability caused by porin loss.13 On the other hand, two-thirds of
the carbapenem-non-susceptible K. pneumoniae isolates (11/
17; 65%) were eventually confirmed as CPE [OXA-48 (n¼7),
KPC type (n¼3) and NDM type (n¼1)]. These results clearly
confirm the trends observed in the national surveillance pro-
gramme showing that K. pneumoniae was by far the most
encountered CPE species and OXA-48 the most frequent carba-
penemase in Belgium.4,5 All PCR-negative CNSE isolates did not
hydrolyse imipenem by the Carba NP assay, thus excluding the
expression of carbapenemases not targeted (or not detected)
by our multiplex PCR assay. Resistance to b-lactams, including
carbapenems, among these non-CPE strains presumably
resulted from AmpC hyperproduction (n¼85, including 8 ESBL
positive), ESBL production (n¼17) and other b-lactamases
(n¼10) in association with impaired permeability due to porin
deficiency.
All but 1 of the 13 confirmed CPE isolates showed intermedi-
ate resistance or resistance to all three carbapenems discs
tested (Table S2, available as Supplementary data at JAC
Online). One OXA-48 K. pneumoniae isolate had an inhibition
zone to meropenem of 23 mm and was therefore categorized
as susceptible according to the CLSI breakpoints. Three other
OXA-48 K. pneumoniae isolates had a 22 mm zone to merope-
nem (intermediately resistant by CLSI criteria), but these would
have been categorized as susceptible according to the EUCAST
breakpoints.9
On the whole, the minimal estimated point prevalence of CPE
was 0.28% (13/4564; 95% CI: 0.13%–0.44%) and ranged per
centre from 0% (for 16 centres) to 1.5%. It is, however, of
concern that one-third (8/24) of the participating laboratories
had isolated at least one CPE isolate in their institution during
the study period and that in only two cases (one KPC positive
and one NDM positive) had the patient travelled abroad, suggest-
ing the probable acquisition and importation of CPE from foreign
countries. In a prospective multicentre study in 35 Spanish hos-
pitals in 2009, Miro´ et al.14 reported a prevalence rate of CPE of
0.04%, but only the presence of metallo-b-lactamases was
sought in this survey. Another survey in 25 Italian laboratories
in 2011 found a point prevalence of CNSE among inpatients
(3.5%) similar to our results. However, most CNSE (87%) were
K. pneumoniae (largely confirmed as KPC producers), in contrast
to the predominance of Enterobacter spp. among CNSE in our
survey.15
The MIC results of the 13 confirmed CPE isolates are detailed
in Table 2. On the basis of CLSI interpretative criteria, all CPE
isolates were found intermediately or fully resistant to ertapen-
em and piperacillin/tazobactam, while five OXA-48-positive
K. pneumoniae isolates had imipenem and/or meropenem MICs
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Table 1. Species/genus distribution and proportion of carbapenem non-susceptibility in Enterobacteriaceae isolates screened in Belgian hospitals




I/Ra CNSE in total
CNSE referred
to the NRC CPE
n % n % n % n % n % n %
E. coli 2580 7 0.3 13 0.5 9 0.3 18 0.7 13 0.5 1 0.04
K. pneumoniae 451 16 3.5 16 3.5 17 3.8 21 4.7 17 3.8 11 2.44
K. oxytoca 211 1 0.5 2 0.9 1 0.5 2 0.9 2 0.9 1 0.47
Enterobacter spp.b 406 14 3.4 52 12.8 67 16.5 90 22.2 72 17.7
Citrobacter spp.c 157 1 0.6 12 7.6 12 7.6 12 7.6
Serratia spp.d 146 2 1.4 8 5.5 4 2.7 9 6.2 5 3.4
Proteus spp.e 386 1 0.3 NAf 1 0.3
Morganella morganii 151 3 2.0 NAf 1 0.7 3 2.0 2 1.3
Providencia spp.g 25 NAf
Othersh 51 1 2.0 1 2.0 2 3.9 2 3.9
Total 4564 46 1.0 104 2.6 99 2.2 158 3.5 125 2.7 13 0.28
NA, not applicable; NRC, National Reference Centre.
aI/R, intermediate/resistant using 2012 CLSI interpretive criteria.6
bEnterobacter cloacae (n¼259), Enterobacter aerogenes (n¼130) and other Enterobacter spp. (n¼17).
cCitrobacter freundii (n¼75), Citrobacter koseri (n¼68) and other Citrobacter spp. (n¼14).
dSerratia marcescens (n¼133), Serratia liquefaciens (n¼10) and other Serratia spp. (n¼3).
eProteus mirabilis (n¼348), Proteus vulgaris (n¼36) and other Proteus spp. (n¼2).
fSusceptibility rates to imipenem were calculated only for Enterobacteriaceae species other than Proteus spp., M. morganii and Providencia spp.
gProvidencia stuartii (n¼22) and Providencia rettgeri (n¼3).
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Table 2. Clinical data and broth microdilution MICs (mg/L) of 15 antimicrobials for confirmed CPE isolates





species Carbapenemase TMCa CTX CAZ FEP TZP ETP IPM MEM ATM GEN AMK TOB CIP TGC CST
C03 urine medicine no K. pneumoniae OXA-48 .1024 4 ≤0.5 2 .128 4 2 1 ≤0.5 ≤1 ≤4 ≤1 ≤0.25 0.25 0.5
C10 urine surgery no K. pneumoniae OXA-48 512 .64 16 16 .128 2 0.5 0.5 32 ≤1 ≤4 8 .2 0.5 1
C10 urine surgery no K. pneumoniae OXA-48 1024 .64 16 16 128 2 0.5 ≤0.25 32 ≤1 ≤4 8 .2 0.25 1
C12 respiratory ICU no K. oxytoca KPC 16 32 .64 32 .128 16 4 8 .64 2 16 .8 .2 1 0.5
C12 pus medicine Vietnam K. pneumoniae NDM 48 .64 .64 .64 .128 4 4 2 .64 .8 ≤4 8 .2 0.5 .8
C12 respiratory medicine no K. pneumoniae KPC 48 .64 .64 32 .128 16 2 2 .64 .8 .32 .8 .2 1 0.5
C13 respiratory ICU no E. coli OXA-48 768 .64 2 4 128 4 4 8 8 .8 ≤4 4 0.5 ≤0.12 0.5
C15 urine other no K. pneumoniae OXA-48 1024 .64 16 32 .128 1 2 0.5 32 .8 ≤4 .8 .2 0.5 2
C17 screening ICU no K. pneumoniae OXA-48 .1024 .64 .64 .64 .128 .32 4 16 .64 .8 ≤4 .8 .2 2 1
C17 respiratory ICU no K. pneumoniae OXA-48 .1024 2 ≤0.5 ≤0.5 128 4 1 2 ≤0.5 ≤1 ≤4 ≤1 ≤0.25 2 1
C17 screening ICU no K. pneumoniae OXA-48 .1024 .64 32 .64 .128 .32 8 16 64 .8 ≤4 .8 .2 0.5 0.5
C19 urine medicine no K. pneumoniae KPC 64 .64 .64 .64 .128 .32 .32 .32 .64 8 16 .8 ≤0.25 0.5 1
C23 pus medicine Israel K. pneumoniae KPC 1024 .64 .64 .64 .128 .32 32 .32 .64 4 32 .8 .2 0.5 0.5
TMC, temocillin; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; TZP, piperacillin/tazobactam; ETP, ertapenem; IPM, imipenem; MEM, meropenem; ATM, aztreonam; GEN, gentamicin;
AMK, amikacin; TOB, tobramycin; CIP, ciprofloxacin; TGC, tigecycline; CST, colistin.
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within the susceptible category. All CPE isolates, apart from one
KPC-positive Klebsiella oxytoca strain, were resistant to temocillin.
Remarkably, all OXA-48 producers exhibited high-level resistance
to temocillin (MIC ≥512 mg/L), while KPC- and NDM-positive iso-
lates showed more variable temocillin MIC levels (16–1024 mg/L).
Only one NDM-positive K. pneumoniae was resistant to colistin
and two OXA-48-positive K. pneumoniae showed intermediate
resistance to tigecycline.
Our study has some limitations. First, 20% of the CNSE iso-
lates detected locally were not referred to the reference labora-
tory, suggesting that the CPE prevalence of 0.28% should be
considered as a minimal estimate. Also, the carriage rate of
CPE is probably underestimated because most isolates were
collected from clinical specimens and not from CPE screening
samples, which are still rarely taken in Belgian hospitals.
Finally, only the subset of CNSE isolates were screened for
CPE, thus not excluding the possible occurrence of poorly
expressed carbapenemases among carbapenem-susceptible
isolates. Previous studies have suggested that the susceptibility
breakpoints of carbapenems should be modified for optimizing
the detection of CPE.16,17 We believe indeed that additional
evaluations are necessary to further improve the accuracy of
laboratory detection strategies of CPE, including adjustment
of the currently recommended screening cut-offs for carbape-
nems and/or the consideration of other antimicrobial
markers, such as associated high-level resistance to temocillin
and piperacillin/tazobactam.
In conclusion, the prevalence of CNSE is low in Belgian hospi-
tals, although CPE strains were detected in one-third of the par-
ticipating centres. Overall, carbapenemases were found mostly in
K. pneumoniae, emphasizing that detection efforts should be
concentrated on this species. Further studies are warranted to
monitor trends over time and to evaluate the prevalence of
CPE carriage in hospitals as well as in other medical-care
sectors, such as nursing homes.
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